GleamWall
中文EN

PRTA PROTHENA CORP PUBLIC LTD CO

Pharmaceutical Preparations · Nasdaq · SEC CIK 1559053 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY347.4%
TTM net income YoY91.5%
TTM EPS YoY91.3%
Revenue 3-yr CAGR-27.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-64.6%
Net margin-45.4%
FCF margin—
EBITDA margin-63.1%

Returns

ROE-8.5%
ROA-7.5%
ROIC (approx.)—
Asset turnover0.17x

Leverage & solvency

Liabilities / assets5.2%
Debt / equity0.00x
Current ratio23.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.31x
Accruals ratio2.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$9.68M$135.16M
R&D expense$134.85M$222.52M
SG&A expense$59.39M$67.20M
Operating income-$214.64M-$154.56M
Pretax income-$200.83M-$128.93M
Income tax$43.26M-$6.62M
Net income-$244.09M-$122.31M
EBITDA-$213.75M-$153.67M
EPS (basic)-4.53-2.27
EPS (diluted)-4.53-2.27
Weighted avg. shares (diluted)53.83M53.77M
Banking
Net interest income$14.14M$25.82M
Balance sheet
Cash & equivalents$307.53M$472.25M
Receivables—$0
Current assets$315.19M$485.41M
PP&E, net$2.14M$3.08M
Total assets$326.80M$547.11M
Current liabilities$40.84M$48.50M
Total liabilities$46.33M$60.18M
Shareholders' equity$280.47M$486.93M
Shares outstanding53.83M53.83M
Cash flow statement
Operating cash flow-$163.58M-$150.05M
Investing cash flow-$138,000-$298,000
Financing cash flow-$139,000$1.55M
Depreciation & amortization$895,000$893,000
Stock-based compensation$37.64M$45.96M

Free plan shows the latest 2 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.